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β-Glucuronidase is an enzyme often employed to de-conjugate β-glucuronides during urinary 
drug testing for benzodiazepines. It is commonly accepted that use of β-glucuronidase is a 
preferred method of hydrolysis over acid-catalysed hydrolysis, which is known to induce 
benzodiazepine degradation and transformation. Literature to date, however, has not reported 
any cases of benzodiazepine transformation initiated by commercial β-glucuronidase 
products. In this study, urine specimens containing either oxazepam or oxazepam glucuronide 
were incubated with β-glucuronidase enzymes obtained from Escherichia coli, Helix 
pomatia, and Patella vulgata under various incubation conditions. After liquid-liquid 
extraction, the extract was analysed by both liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) and gas chromatography-mass spectrometry (GC-MS) for the 
presence of benzodiazepines. All three enzyme preparations examined were capable of 
reducing oxazepam or oxazepam glucuronide into nordiazepam (desmethyldiazepam). 
Nordiazepam formation was positively correlated with incubation temperature, incubation 
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time, oxazepam concentration and enzyme concentration. Under all enzymatic hydrolysis 
conditions investigated, the percentage of nordiazepam formation is <2.5% relative to the 
amount of oxazepam present in the system. The findings of this study have both clinical and 
forensic implications and it is clear that the detection of nordiazepam in biological samples 




Benzodiazepines are widely prescribed for their sedative, hypnotic, muscle relaxant and 
anticonvulsant properties. They are also associated with misuse and abuse and implicated in 
crimes such as drug-facilitated sexual assault (1,2). Consequently, benzodiazepines are 
among the most frequently encountered substances in clinical and forensic toxicological 
analyses. Concentrations of benzodiazepines and their metabolites are highest in urine than in 
other biological specimens such as blood, oral fluids and hair, making urine one of the 
preferred matrices for drug analysis. Since the majority of metabolites of benzodiazepines 
present in urine are in the form of glucuronide conjugates, a hydrolysis step to cleave these 
conjugates prior to either GC-MS analysis or LC-MS/MS analysis has been adapted by many 
laboratories involved in urinary drug testing of benzodiazepines. It has been well documented 
that hydrolysis by β-glucuronidases obtained from sources such as Escherichia coli (E. coli), 
Helix pomatia (H. pomatia), Patella vulgata (P. vulgata) or bovine liver (3,4) is preferred 
over hydrolysis by acid, as the latter decomposes some benzodiazepines into common 
benzophenones and thus renders unequivocal identification of target drugs impossible (5-7). 
 
Many benzodiazepine metabolites are also biologically active and these active metabolites 
are marketed as drug products in their own right. For example, the drug substance in 
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Serepax® is oxazepam which is a metabolite of diazepam (marketed as Valium®). Detection 
of oxazepam in a biological fluid may not necessarily be an indication of oxazepam use, as it 
could be a metabolite of temazepam, diazepam and many other drugs such as clorazepate, 
prazepam, and medazepam (8). Diazepam, on the other hand, can be a thermal degradation 
product of ketazolam (9), as well as a metabolite of tetrazepam (10). These observations 
reveal the challenging nature of interpreting benzodiazepine drug testing results. 
 
In this study, the authors wish to report a novel reduction reaction of oxazepam to 
nordiazepam (desmethyldiazepam) observed during enzymatic treatment of urine specimens. 
The findings of this study further highlight the complexity of interpreting drug testing results 
associated with benzodiazepines. 
 
Material and methods 
 
Chemicals and reagents 
Individual ampoules of oxazepam and nordiazepam (at 1 mg/mL in methanol) and α-hydroxy 
alprazolam-d5 (HO-Alp-d5, as internal standard, at 0.1 mg/mL) were supplied from Cerilliant 
(Austin, TX). Three β-glucuronidase preparations were purchased from Sigma-Aldrich 
(Castle Hill, NSW, Australia): E. coli Type VII-A, lyophilized powder, 12,495,000 units/g 
protein; P. vulgata Type L-II, lyophilized powder, 2,262,000 units/g solid; H. pomatia Type 
H-3, aqueous solution, 99,000 units/mL. Derivatizing reagent 
bistrimethylsilyltrifluoroacetamide (BSTFA) containing 1% trimethylchlorosilane (TMCS) 
was purchased from United Chemical Technologies (Bristol, PA).Water was purified by a 
Milli-Q system obtained from Millipore (Sydney, Australia). All solvents and other 
chemicals were analytical grade or better.  
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Enzymatic hydrolysis of urine specimen 
All enzyme stock solutions were prepared at a concentration of 50,000 units/mL with buffer 
solutions. E. coli β-glucuronidase was dissolved in 1 M sodium phosphate buffer pH 6.8. P. 
vulgata β-glucuronidase was prepared in 1 M ammonium acetate buffer pH 4.5. H. pomatia 
β-glucuronidase was diluted with 1 M ammonium acetate buffer pH 4.5. 
 
A blank urine specimen was obtained from a donor without any medication of 
benzodiazepines. Positive urine samples for oxazepam were obtained from the Toxicology 
Unit, Pacific Laboratory Medicine Services, Macquarie Hospital, North Ryde, NSW, 
Australia. The samples were residual specimens from patients on oxazepam medication and 
were supplied after de-identification. All patient samples had been kept refrigerated by the 
testing laboratory for 1 to 2 weeks before they were used in this study. 
 
Into 1mL of the above urine specimens in a 10-mL screw-cap test tube were added 250 ng of 
HO-Alp-d5 (internal standard, 50 µL of 5 µg/mL HO-Alp-d5 solution) and 1500 units of β-
glucuronidase (30 µL of 50,000 units/mL enzyme solutions). After addition of 1 mL of 1 M 
sodium phosphate buffer pH 6.8 for E. coli enzyme, or 1M ammonium acetate buffer pH 4.5 
for H. pomatia enzyme and P. vulgata enzyme, the samples were incubated under the 
specified conditions. 
 
To assess the effect of β-glucuronidase on reduction of oxazepam (as free base), the 
following experimental procedures were followed. Into 1mL of blank urine in a 10-mL 
screw-cap test tube were added 250 ng of HO-Alp-d5, 100,000 ng of oxazepam (100 µL of 
1mg/mL stock solution) and 1500 units of β-glucuronidase unless otherwise specified. After 
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addition of 1 mL of 1 M sodium phosphate buffer pH 6.8 for E. coli enzyme, or 1M 
ammonium acetate buffer pH 4.5 for H. pomatia enzyme and P. vulgata enzyme, the samples 
were incubated under the specified conditions. 
 
Liquid-liquid extraction 
Into the above enzyme-treated samples were added 0.5 mL 2 M sodium hydroxide solution 
and 5 mL extracting solvent dichloromethane/isopropanol (9:1). The samples were mixed on 
a vortex mixer for 2 min and centrifuged at 3000 rpm for 10 min. After aspirating the top 
aqueous layer into waste, the bottom organic layer was treated with anhydrous sodium 
sulphate. The organic layer was transferred into a clean set of tubes and dried under a gentle 
stream of nitrogen at 30°C. The dried extract was then reconstituted in 200 µL of acetonitrile 
for both GC-MS and LC-MS/MS analyses. 
 
GC-MS 
Trimethylsilyl (TMS) derivatives of benzodiazepines were prepared for GC-MS analysis. 
Aliquots of 50 µL of the above acetonitrile extract were transferred into a high recovery MS 
vial (1.5mL, Agilent Technologies, Melbourne, Australia). After addition of 50 µL of BSTFA 
with 1% TMCS into each sample, the vial was capped and heated at 75ºC for 20 min. A 
previously published GC-MS method (11) was modified and adapted in this study. Briefly, 
GC-MS analysis was carried out on an Agilent 6890/5973 GC-MS equipped with an 
autoinjector and a HP-5MS 5% phenyl methyl siloxane cross-linked capillary GC column (30 
m × 0.25-mm i.d., 0.25-µm film thickness, Agilent Technologies, Forest Hill, Australia). 
Injections (2 µL) were made in splitless mode with helium as a carrier gas at a constant flow 
of 1 mL/min. The inlet temperature was set to 240°C and the transfer line to 280°C. The oven 
temperature was maintained at 160°C for 1 min and then programmed at 30°C/min to a final 
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temperature of 325°C, which was held for 5 min. The MS was operated in selective ion 
monitoring (SIM) mode. The ions monitored included m/z 341, 342, 327 for nordiazepam 
(RT 5.04 min), 429, 341, 313 for oxazepam (RT 5.52 min), and 386, 401, 351 for HO-Alp-d5 
(RT 9.16 min). The first ion for each compound was used as the quantifying ion, and others 
were used as the qualifying ions. For positive identification of analytes, the retention time and 




Aliquots of the above acetonitrile extract (50 µL) were mixed with an equal volume of 5 mM 
ammonium acetate aqueous solution for LC-MS/MS study. Analyses were performed on a 
PerkinElmer SCIEX API365 LC-MS/MS instrument equipped with a Turbo IonSpray source, 
a PerkinElmer Series 200 autosampler, a micro PerkinElmer series 200 LC pump, and an on-
line vacuum degasser. The Alltima C18 column (150 mm x 2.1-mm i.d., 5-µm particle size, 
Grace Davison Discovery Sciences, Sydney, Australia) was maintained at 28ºC. The mobile 
phase consisted of 25% water containing 5 mM ammonium acetate and 75% methanol. The 
flow rate was 0.5 mL/min and the injection volume was 5 µL. 
 
The MS was run in selected reaction monitoring (SRM) mode using the Sample Control 1.4 
program. Nitrogen was used as the nebulizing gas of the Turbo IonSpray, curtain gas and 
collision gas. A flow rate of 1.25 L/min was set for both the nebulizing gas and the curtain 
gas. The electrospray ion source voltage was +5000 V, the source temperature was 350°C, 
and the orifice voltage was +46 V. The ring voltage was +210 V, the Q0 energy was -10 V, 
and the RO2 energy was -48 V in order to give collision energy of 38 V. The SRM transitions 
monitored were m/z 271.0 (Q1)  140.0 (Q3), m/z 271.0 (Q1)  165.0 (Q3) for 
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nordiazepam; m/z 287.0 (Q1)  241.0 (Q3), m/z 287.0 (Q1)  269 (Q3) for oxazepam; and 
m/z 330.0 (Q1)  302.0 (Q3) for HO-Alp-d5. The first transition for each compound was 
used for quantitation. The dwell time for each transition was 400 msec. The retention times 
for HO-Alp-d5, oxazepam and nordiazepam were at 2.51 min, 2.78 min and 3.52 min, 
respectively. For positive identification of analytes, the retention time and ion ratios must be 
within ±2% and ±20%, respectively, when compared to those of the calibrating standards. 
 
Method validation 
The liquid-liquid extraction method employed in this study yielded >95% recovery of the 
benzodiazepines when tested on pure standards (500 ng/mL in urine) without undergoing 
enzymatic hydrolysis procedures. However, the recoveries varied significantly when an 
enzymatic hydrolysis step was included. For example, when the benzodiazepines were 
incubated with H. pomatia enzyme (pH 4.5) at 50°C for 18h, the recoveries were found at 
55%, 88% and 93% for oxazepam, nordiazepam and HO-Alp-d5, respectively. The recoveries 
become 85%, 90%, and 94% when they were incubated with E. coli enzyme (pH 6.8) at 22°C 
for 24h.  
 
A four-point calibration was performed at concentrations of 50, 100, 300, and 500 ng/mL 
benzodiazepines for both GC-MS and LC-MS/MS methods. Into 1 mL of blank urine was 
added 5, 10, 30 and 50 µL of 10 µg/mL mixed benzodiazepine standards containing 
oxazepam and nordiazepam to give a final concentration of 50, 100, 300, and 500 ng/mL 
benzodiazepines, correspondingly. After adding 250 ng HO-Alp-d5 (internal standard) and 
1500 units of β-glucuronidase into each sample, enzymatic hydrolysis and extraction 
procedures described above were followed. To determine the limit of detection (LOD) and 
the linearity range, a series of standards with concentrations both below the lowest calibrator 
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(50 ng/mL) and above the highest calibrator (500 ng/mL) were prepared and analysed 
together with the calibration standards. For both oxazepam and nordiazepam, the limit of 
detection (LOD) was at 2 ng/mL in the GC-MS method and 5 ng/mL in the LC-MS/MS 
method. The lower limit of quantitation (LLOQ) was found at 5 ng/mL in the GC-MS method 
and 10 ng/mL in the LC-MS/MS method. The upper limit of quantitation (ULOQ) was found 
at 5,000 ng/mL in both the GC-MS and the LC-MS/MS methods. The LLOQ and ULOQ 
were determined following conventional definitions, that is, acceptable retention times (± 
2%), ion ratios (± 20%) and quantitative values (± 20% of the nominal values). The LOD was 
subject to all criteria except the ± 20% quantitative adherence. Therefore the linearity range 
determined was 5 ng/mL to 5,000 ng/mL for the GC-MS method and 10 ng/mL to 5,000 
ng/mL for the LC-MS/MS method. In cases where oxazepam concentrations were above the 
ULOQ, the samples were re-analysed after appropriate dilution with blank urine so that the 
concentrations were within the linearity range. 
 
Due to the different recoveries of the three benzodiazepines under different incubation 
conditions observed above, a 4 point calibration curve was needed for each incubation 
condition investigated in the study. Calibration curves were linear with correlation coefficient 
values ranging from 0.9940 to 0.9999 for all hydrolysis conditions employed and for both 
GC-MS and LC-MS/MS methods. Two quality control (QC) specimens were also included 
whenever a calibration curve was constructed in the study. The first QC sample contained 
200 ng/mL of nordiazepam and oxezapam. The second QC sample contained 2,000 ng/mL of 
nordiazepam and oxazepam. The QC samples were prepared by adding appropriate amounts 
of nordiazepam and oxazepam standards into blank urine. All QC results were within ±20% 
of the expected values for each enzymatic hydrolysis condition investigated.  
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To investigate the matrix effect, benzodiazepine standards including oxazepam, nordiazepam 
and HO-Alp-d5 (250 ng each) were added to 200 µL acetonitrile (solvent) or to 200 µL 
acetonitrile extract of a urine blank (urine). Analyses of the two samples revealed that there 
was no noticeable difference in absolute peak areas of the SRM signals for each compound 
between the two samples. The same results were obtained on 3 repeat experiments. Peak 
areas for urine samples were calculated at 92% for nordiazepam, 95% for oxazepam and 99% 
for HO-Alp-d5 relative to those of the solvent alone. These results indicated that there was no 




Formation of nordiazepam during β-glucuronidase catalysed hydrolysis of oxazepam 
glucuronide in patient urines 
A urine sample from a patient on oxazepam medication was analysed for the presence of 
benzodiazepines by using both GC-MS and LC-MS/MS methods. Urine specimens were 
hydrolysed with 1500 units of β-glucuronidase (+Enzyme) from 3 different preparations, i.e. 
E. coli, H. pomatia, and P. vulgata. The samples were incubated at 22°C for 24 h, 37°C for 
24 h, and 60°C for 2 h for each enzyme studied. To assess the amount of free 
benzodiazepines in the specimens, enzyme-free specimens (-Enzyme) were included in the 
study for each incubation condition and were analysed in the same manner. The results are 
summarized in Table I. Total oxazepam in the sample after enzymatic hydrolysis 
(Oxazepam+Enzyme) was determined at around 200,000 ng/mL. Free oxazepam in the 
sample was around 2,500 ng/mL judged from the values obtained when no enzyme was 
introduced into the specimen (Oxazepam-Enzyme). The nordiazepam concentration averaged 
20 ng/mL (14-26 ng/mL) when no enzyme was present in the hydrolysis step. Its 
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concentration was elevated significantly in samples where enzyme was added. For instance, 
when the samples were incubated with H. pomatia β-glucuronidase at 22°C for 24 h, 37°C 
for 24 h and 60°C for 2 h, the concentrations of nordiazepam were detected at 66 ng/mL, 854 
ng/mL, and 550 ng/mL, respectively, when measured by LC-MS/MS. The identity of 
nordiazepam found in these enzyme treated specimens was also confirmed by GC-MS 
analysis in SCAN mode of the extracted samples. Its full scan (100-300amu) spectrum 
matched very well with that of nordiazepam reference standard (Figure 1). The identification 
of nordiazepam was further confirmed by co-eluting of added nordiazepam to the extracted 
positive samples (Figure1, TIC trace C).  
 
To assess the effect of enzyme treatment on the formation of nordiazepam from oxazepam, 
more urine specimens of oxazepam users were collected and analysed. Three enzymatic 
hydrolysis conditions i.e. 22°C for 24 h with E. coli, 60°C for 2 h with H. pomatia, and 50°C 
for 18 h with H. pomatia were investigated in this experiment. The nordiazepam detected 
relative to the oxazepam present in the same sample under these hydrolysis conditions was in 
the range of 0.02%-0.03%, 0.20-0.41%, and 0.85%-2.50%, correspondingly. The individual 
results were summarized in Table II.  
 
Formation of nordiazepam from incubation of oxazepam (free base) with β-
glucuronidase enzymes 
Oxazepam (as free base) at 100,000 ng/mL was incubated with E. coli, P. vulgata, and H. 
pomatia β-glucuronidase (1000 units/mL) at 50°C for 18 h. LC-MS/MS analyses of the 
samples showed that nordiazepam was produced at concentrations of 78 (±11), 354 (±38), 
and 876 (±82) ng/mL, respectively. The values were means from three experiments with 
standard deviation in brackets. H. pomatia produced the highest concentration of 
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nordiazepam, while E. coli yielded the least. GC-MS analyses gave very similar results (data 
not shown). No nordiazepam was detectable in the control experiments in which oxazepam 
(100,000 ng/mL) was incubated under the same conditions without the presence of enzymes 
for each enzymatic condition (LOD for nordiazepam 2 ng/mL in the GC-MS method and 5 
ng/mL in the LC-MS method).  
 
In a separate experiment, oxazepam standard (250,000 ng/mL) was prepared in acetonitrile 
and was checked for the presence of nordiazepam impurity by both the GC-MS and the LC-
MS/MS methods without any enzymatic hydrolysis and extraction process. No nordiazepam 
was detectable using both methods, indicating that the oxazepam standard sourced from 
Cerilliant was free from nordiazepam contaminants.  
 
Incubation temperature effect 
Oxazepam at 100,000 ng/mL was incubated with H. pomatia β-glucuronidase (1500 
units/mL) for 18 h at 22°C, 37°C and 50°C. LC-MS/MS analyses of the samples showed that 
nordiazepam formation was positively correlated with the incubation temperature (Figure 2). 
When the incubation temperature was at 22°C, only 10 ng/mL nordiazepam was produced. 
Nordiazepam production was increased to 475 ng/mL and 1450 ng/mL when the incubation 
temperature was at 37°C and 50°C, respectively. When enzyme was omitted from the 
incubation mixture, no nordiazepam was detectable for each incubation temperature studied. 






Incubation time effect 
Oxazepam at 100,000 ng/mL was incubated with H. pomatia β-glucuronidase (1500 
units/mL) at 50°C for 0, 1, 2 and 5 h. LC-MS/MS analyses of the samples showed that 
nordiazepam formation was positively correlated with the incubation time (Figure 3). The 
concentrations of nordiazepam formed from the incubation mixture were 17, 67, and 375 
ng/mL, which corresponded to 1, 2, and 5 h of incubation, respectively. No nordiazepam was 
detectable at 0 h incubation time point. 
 
Enzyme concentration effect 
Oxazepam at 100,000 ng/mL was incubated with various concentrations of H. pomatia β-
glucuronidase at 50°C for 18 h. LC-MS/MS analyses of the samples showed that 
nordiazepam formation was positively correlated with the enzyme concentration. 
Nordiazepam was produced from the incubation mixture at 253 (±18), 1444 (±89), and 1874 
(±113) ng/mL, when 250, 1500, and 2500 units/mL enzymes were used correspondingly. The 
values were means from three experiments with standard deviation in brackets. No 
nordiazepam was detectable in the control experiments in which oxazepam (100,000 ng/mL) 
was incubated under the same conditions without the presence of H. pomatia enzymes. 
 
Oxazepam concentration effect 
Oxazepam at 30,000 ng/mL, 50,000 ng/mL, and 100,000 ng/mL was incubated with H. 
pomatia β-glucuronidase (1500 units/mL) at 50°C for 18 h. LC-MS/MS analyses of the 
samples showed that nordiazepam was detected at 605 (±43), 813 (±60), 1450 (±75) ng/mL, 
respectively. The values were means from three experiments with standard deviation in 
brackets. When oxazepam was incubated under the same conditions without the addition of 
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It is a common knowledge that β-glucuronidase-mediated hydrolysis is preferred over acid-
catalysed hydrolysis, which is known to induce benzodiazepine degradation and 
transformation. The commonly used β-glucuronidases are prepared from different sources 
such as H. pomatia, P. vulgata, E. coli, and bovine liver. The enzymatic hydrolysis 
conditions reported in the literature vary widely, with incubation temperature ranging from 
22ºC to 65ºC and incubation time ranging from 30 min to 24 h (2,3,11-15). In this study, β-
glucuronidase enzymes were obtained from three different sources, i.e. E. coli, H. pomatia, 
and P. vulgata. Several incubation conditions were also applied. Meatherall conducted a 
systematic investigation of enzymatic hydrolysis conditions and found that prolonged 
incubation at 56ºC led to a loss of benzodiazepines and not all benzodiazepines were 
destroyed at the same rate (3). This varying degree of degradation was also observed in this 
study. For example, the recoveries for oxazepam and nordiazepam were determined at 55% 
and 88% respectively when they were incubated with H. pomatia enzyme (pH 4.5) at 50°C 
for 18 h. The recoveries become 85% and 90% when they were incubated with E. coli 
enzyme (pH 6.8) at 22°C for 24 h. Under these circumstances, deuterated oxazepam and 
nordiazepam would be ideal internal standards to use so that these variations in recoveries 
can be compensated. Although oxazepam-d5 and nordiazepam-d5 are readily available 
commercially, they are not considered suitable for this study. Since the current study was 
focused on the conversion of oxazepam to nordiazepam mediated by β-glucuronidase 
treatment, conversion of oxazepam-d5 to nordiazepam-d5 would also be expected to take 
 14 
place under the experimental conditions, which inevitably leads to analytical measurement 
inaccuracy. HO-Alp-d5 is readily available and was chosen over other potential candidates 
based on two key considerations. Firstly, HO-Alp-d5 shows a good recovery (around 94%) 
under all hydrolysis conditions investigated in the study. Secondly, HO-Alp-d5 shows good 
peak shape and signal response in both GC-MS and LC-MS/MS. The major drawback of 
using HO-Alp-d5 was the need to include a calibration curve and QC samples for each 
hydrolysis condition studied. This had increased considerably the volume of sample analysis 
and analytical time. However, the methods developed showed good reproducibility and 
linearity over a wide range and do not compromise analytical accuracy in any way. Another 
shortcoming of the method was the use of mixed standard solutions of oxazepam and 
nordiazepam in the preparation of both calibrators and QC specimens. There would be small 
conversion of oxazepam into nordiazepam in these samples during hydrolysis, leading to 
inaccurate nordiazepam calibration curves and QC results. Separate calibrators and QC 
samples containing just nordiazepam and just oxazepam would avoid this inaccuracy. 
However, the contributions were relatively insignificant (less than 2.5%) and were not to alter 
the results and conclusions of the study. 
 
In the experiment to investigate the occurrence of nordiazepam in a urine specimen from a 
patient prescribed oxazepam, three incubation conditions were explored, i.e. 22ºC for 24 h, 
37ºC for 24 h, and 60ºC for 2 h. As shown in Table I, the total oxazepam concentration in 
each hydrolysis conditions investigated was in the vicinity of 200,000 ng/mL. The free 
oxazepam in the sample was determined at around 2500 ng/mL, which accounts for less than 
2% of the conjugated oxazepam glucuronide present in the urine sample. This result is in 
agreement with the current knowledge that oxazepam is extensively conjugated in urine as 
oxazepam glucuronide. O’Neal and Poklis (12) reported that incubation for 2 h at 60ºC or 24 
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h at 22ºC with H. pomatia enzyme was optimal for oxazepam and lorazepam glucuronides 
and hydrolysis was complete at both conditions. It is therefore plausible to suggest that a 
complete hydrolysis of oxazepam glucuronide was achieved under all hydrolysis conditions 
investigated in the current study. It is evident from the results summarized in Table I that 
nordiazepam levels were elevated in all samples that underwent enzymatic hydrolysis when 
compared to those in the enzyme-free control samples. Incubation for 24 h at 22ºC resulted in 
the least increase in nordiazepam concentration for all three β-glucuronidase enzymes 
examined. Incubation for 24 h at 37ºC led to the most increase in nordiazepam concentration. 
The increase in nordiazepam concentration were modest when hydrolyses were conducted at 
60ºC for 2 h. Although the origin of the small quantity of nordiazepam (at approximately 20 
ng/mL) detected in the urine sample without enzyme treatment is unknown, enterohepatic 
circulation of oxazepam and its reduction to nordiazepam by the action of intestinal bacteria 
as previously reported by Okamura and co-authors (16) might offer a feasible explanation. 
However this reductive conversion of oxazepam to nordiazepam by intestinal bacteria cannot 
account for the elevated levels of nordiazepam after enzymatic hydrolysis observed in this 
study (see Table I). Firstly, the degree of nordiazepam elevation is different among the 
hydrolysis conditions examined. Secondly, results from the experiments in which oxazepam 
(as free base instead of its glucuronide conjugate) was incubated with β-glucuronidase under 
various conditions support an alternative explanation that the enzyme preparations has the 
capacity to reduce oxazepam into nordiazepam (Figure 4). This reductive transformation is a 
novel discovery. As such, it was critical to unequivocally identify nordiazepam using 3 
different analytical methods, GC-MS analysis of its TMS derivative in SIM mode, GC-MS 
analysis of the underivatized urine extract in SCAN mode (100-300amu), and LC-MS/MS 
analysis of the underivatized urine extract in SRM mode. 
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It is anticipated that the reduction reaction observed may take place on the glucuronide-bound 
oxazepam as well as on the free oxazepam released during the enzyme-catalysed hydrolysis. 
Although it is difficult to assess which form of oxazepam is the favoured substrate, it is 
relatively easy to demonstrate that the released oxazepam free base takes part in the observed 
reductive transformation process. It was therefore decided to source commercial oxazepam 
(free base) instead of oxazepam glucuronide for conducting further investigation. The 
oxazepam (free base) was purchased from Cerilliant and was found to be free of any 
detectable nordiazepam contaminants.  
 
When oxazepam (free base) was incubated with β-glucuronidase for 18 h at 50ºC, formation 
of nordiazepam was observed in all three enzyme-treated samples. There was no detectable 
nordiazepam in the corresponding controls when enzymes were not present while all other 
parameters such as the incubation time, incubation temperature, and the pH condition were 
matched. The results indicate conclusively that formation of nordiazepam is not a result of 
thermolysis of oxazepam (17), but a direct action of enzyme treatment. The reduction 
reaction was positively correlated with the reaction temperature (Figure 2), incubation time 
(Figure 3), oxazepam concentration, and enzyme concentration under the experimental 
conditions described in this study. When the same units of enzymes were used, E. coli 
enzyme produced the least amount of nordiazepam, while H. pomatia enzyme yielded the 
most products. Based on the product information provided by Sigma-Aldrich, E. coli β-
glucuronidase contains buffer salts and stabilizers, while P. vulgata enzyme contains 
sulfatase activity and H. pomatia enzyme possesses sulfatase and sometimes acid 
phosphatase activities. Since neither β-glucuronidase nor sulfatase was reported in the 
literature to be involved in mediating reductive reactions in a biological or a chemical system, 
a great caution should be exercised when trying to link the observed reaction to the hydrolytic 
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enzymes. It is clear further studies are needed to identify the responsible component(s) in the 
β-glucuronidase enzymes so that investigation into the reaction mechanisms can become 
possible.  
 
Urinary drug testing for benzodiazepines in many laboratories in Australia is performed to 
Australian/New Zealand Standard AS/NZS 4308 (18). According to the standard, the 
confirmatory test cut-off level for reporting positive nordiazepam in urine is 200 ng/mL. It is 
clear from our study that enzymatic hydrolysis is a potential source of producing false 
positive results for nordiazepam. Depending on the hydrolysis condition used, varying 
amounts of nordiazepam artefact can be produced. As summarized in Table II, when 
incubating for 24 h at 22ºC with E. coli β-glucuronidase, the nordiazepam formed is <0.04% 
relative to the amount of oxazepam present and is less likely to produce a false positive 
result. When incubating for 2 h at 60ºC with H. pomatia enzyme, the percentage of 
nordiazepam formation ranged from 0.2% to 0.4%. A specimen containing 50,000 ng/mL 
oxazepam could yield a false positive nordiazepam result with a concentration greater than 
200 ng/mL. If overnight incubation (18 h) at 50ºC with H. pomatia enzyme was employed, 
the artefact formation ranged from 0.9% to 2.5%. A specimen with as low as 8,000 ng/mL 
oxazepam is likely to produce a false positive nordiazepam result. Depending on the 
enzymatic hydrolysis conditions applied, nordiazepam artefact formation could have 
significant implication on benzodiazepine reporting.  
 
Based on the results of the current study, the observed reduction of oxazepam to nordiazepam 
can be minimised if E. coli β-glucuronidases are used and the condition of 24 h incubation at 
22ºC is applied. However, hydrolysis involving E. coli enzyme is known to give lower yields 
for other benzodiazepines such as lorazepam from their glucuronide conjugates (3). In drug 
 18 
testing industries, many laboratories that perform urinary drug testing services for multiple 
drugs may choose to hydrolyse and extract these drugs, e.g. benzodiazepines, opiates and 
other basic substances in one single sample preparation step, in order to cut down costs and 
improve turn-around time. It is well known that opiate glucuronides, especially codeine 
glucuronide, are difficult to de-conjugate by β-glucuronidase and require incubation for 
longer period of time (16-24 h) at higher temperature e.g. 60ºC (19,20). Significant reduction 
of oxazepam when present at high concentrations in urine is expected to occur under such 
conditions. Due to variables in enzyme type, source of supply and amount used, as well as 
differences in incubation time and incubation temperature, it is advisable that laboratories 
perform their own assessment on the extend of nordiazepam artefact formation under their 
specific analytical conditions. It is clear that where high levels of oxazepam with 
corresponding low amounts of nordiazepam and no other benzodiazepines (e.g. temazepam) 





A novel transformation of oxazepam during enzyme hydrolysis has been discovered in this 
study. Incubation of commercial β-glucuronidase preparations with either oxazepam 
glucuronide in patient urines or oxazepam free base added to a blank urine results in 
formation of nordiazepam. The finding of this study adds another layer of complexity to the 
challenging field of urinary drug testing for benzodiazepines and will have both clinical and 
forensic implications. The presence of nordiazepam in biological samples subjected to 
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Figure 1. GC-MS identification of nordiazepam (non-derivatized) from a patient urine 
specimen following hydrolysis by H. pomatia enzyme at 60°C for 2 h. A) nordiazepam 
reference standard (20 µg/mL in methanol, RT 6.76 min); B) patient urine extract; C) mixture 
of samples A and B in equal volume; D) mass spectrum of nordiazepam standard from TIC 
trace A; E) mass spectrum of nordiazepam identified in patient urine specimen from TIC 
trace B. GC injection was done in split mode with a split ratio of 30:1 and an injection 
volume of 1 µL. The oven temperature was maintained at 200°C for 0.5 min and then 
programmed at 15°C/min to a final temperature of 300°C, which was held for 3 min. The MS 
was operated in SCAN mode (100-300 amu). All other GC-MS conditions were similar to 











































Figure 2. Formation of nordiazepam from incubation of oxazepam (at 100,000 ng/mL) with 
H. pomatia β-glucuronidase (1500 units/mL) for 18 h at various temperatures. Values were 
from LC-MS/MS analyses and were means of 3 measurements with standard deviation 
represented by the error bars. No nordiazepam was detectable in the enzyme-free control 
samples for each incubation condition investigated. The results were collectively represented 











































Figure 3. Formation of nordiazepam from incubation of oxazepam (at 100,000 ng/mL) with 
H. pomatia β-glucuronidase (1500 units/mL) at 50ºC. Values were from LC-MS/MS analyses 












Figure 4. Reductive transformation of oxazepam to nordiazepam observed during enzyme 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































   
